Immunotherapy in Melanoma | Specialty

The OncLive Immunotherapy in Melanoma condition center page is a comprehensive resource for clinical news and expert insights on available and investigational immunotherapies in melanoma and other skin cancers. This page features news articles, interviews in written and video format, and podcasts that focus on updates with checkpoint inhibitors and the ongoing research with this type of treatment.

AMG 510 Shows Clinical Activity in Advanced KRAS G12C-Mutant Solid Tumors

May 30th 2020

AMG 510, a novel KRAS G12C inhibitor, demonstrated early evidence of a consistent safety profile and anticancer activity across a range of advanced KRAS G12C-mutant solid tumors other than non–small cell lung cancer and colorectal cancer.

Dr. Sznol on the Use of Immunotherapy in Melanoma

May 22nd 2020

Mario Sznol, MD, discusses the use of immunotherapy in melanoma.

Novel Combo Elicits Clinical Responses in Patients With "Cold" Melanomas

May 13th 2020

Combining the PD-1 inhibitor pembrolizumab with intratumoral plasmid interkeukin-12 electroporation elicited clinical responses in patients with immunologically quiescent advanced melanoma.

Novel Combo Elicits Clinical Responses in Patients With "Cold" Melanomas

May 13th 2020

Combining the PD-1 inhibitor pembrolizumab with intratumoral plasmid interkeukin-12 electroporation elicited clinical responses in patients with immunologically quiescent advanced melanoma.

Algazi Attests to Benefit of Continuous Dosing of BRAF/MEK Inhibitors in Melanoma

May 6th 2020

Alain Algazi, MD, discusses the SWOG S1320 trial further, the future of intermittent dosing in melanoma, and future clinical trials in the field.

Cemiplimab Shows Strong Activity in Pivotal Basal Cell Carcinoma Trial

May 5th 2020

Cemiplimab induced clinically meaningful and durable responses in patients with advanced basal cell carcinoma.

Neoadjuvant Nivolumab Shows Strong Clinical Activity in Merkel Cell Carcinoma

May 4th 2020

Nivolumab, when administered approximately 4 weeks prior to surgery in patients with Merkel cell carcinoma, was found to be tolerable and to induce pathological complete responses and radiographic tumor regressions.

Dr. Pavlick on the COLUMBUS Trial in Metastatic Melanoma

May 1st 2020

Anna C. Pavlick, DO, discusses updated results from the COLUMBUS trial in metastatic melanoma.

Dr. Algazi on Benefit of Continuous Dabrafenib/Trametinib Dosing in BRAF+ Melanoma

April 30th 2020

Alain Algazi, MD, discusses the benefit of continuous dosing with dabrafenib (Tafinlar) and trametinib (Mekinist) in patients with BRAF mutation–positive advanced melanoma.

Dr. Kudchadkar on the Biological Differences Between Ocular and Cutaneous Melanoma

April 29th 2020

Ragini R. Kudchadkar, MD, discusses the biological differences between ocular melanoma and cutaneous melanoma.

Atezolizumab Plus Vemurafenib/Cobimetinib Impresses in BRAF V600+ Melanoma

April 28th 2020

Treatment with atezolizumab in combination with vemurafenib and cobimetinib was found to significantly improve progression-free survival and produce durable responses versus vemurafenib and cobimetinib alone in treatment-naïve patients with BRAF V600–mutant advanced melanoma.

Continuous Dabrafenib/Trametinib Dosing Improves PFS in BRAF+ Melanoma

April 27th 2020

Continuous dosing with dabrafenib and trametinib improved progression-free survival compared with intermittent dosing in patients with BRAF mutation–positive advanced melanoma.

Novel Therapies Expand Options in Melanoma, But Surgery Retains Role

April 16th 2020

Omid Hamid, MD, discusses emerging treatment approaches, the role of surgery, and ongoing research efforts in melanoma.

Study Tests Novel Doublet Designed to Promote Immunity in cSCC

April 13th 2020

Investigators are testing the hypothesis that administering cetuximab with an anti–PD-L1 agent will induce immunostimulatory synergy and prolong survival in patients with cutaneous squamous cell carcinoma.

T-Cell Therapies Spark Interest in Melanoma, Despite Clinical Challenges

April 11th 2020

Jason J. Luke, MD, FACP, discusses the future of T-cell therapies in melanoma, emerging biomarkers, and ongoing research regarding the gut microbiome.

Ongoing Research Efforts in Metastatic Ocular Melanoma Could Shift Paradigm

April 11th 2020

Ragini Kudchadkar, MD, discusses the prognosis of patients with metastatic ocular melanoma and the work being done to define novel approaches in melanoma.

Dr. Hamid on Promising Triplet Combinations Under Exploration in Melanoma

April 11th 2020

Omid Hamid, MD, discusses promising triplet combination under exploration in melanoma.

STP705 Shows Promise in Cutaneous Squamous Cell Carcinoma

April 10th 2020

STP705 met the primary efficacy end point in an ongoing phase II study of patients with cutaneous squamous cell carcinoma in situ.

Lifirafenib Active in Melanoma, Other Solid Tumors

April 9th 2020

The investigational RAF inhibitor lifirafenib demonstrated antitumor activity in patients with melanoma and other solid tumors.

Dr. Pavlick on Sequencing Challenges in BRAF-Mutant Melanoma Treatment

March 31st 2020

Anna C. Pavlick, DO, discusses sequencing challenges faced in the treatment of patients with BRAF-mutant melanoma.